Clinical Trial

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).
Protocol Amendment History 3 changes
notable Primary completion pushed: 2029-10 -> 2030-02 2026-08-07
minor Completion pushed: 2030-10 -> 2031-02 2026-08-07
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07455903
Lead Sponsor Baptist Health South Florida
Collaborators: Blue Earth Diagnostics
Conditions Prostate Cancer, Localized Prostate Carcinoma
Enrollment 50 participants
Start Date 2026-07-29
Primary Completion 2030-02 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06